Regeneron Lays Out Commercial Case For Arcalyst In Gout Flares To Investors; Convincing Payers May Be Challenge
This article was originally published in The Pink Sheet Daily
Executive Summary
During the biopharma's first ever investor day, management outlines early plans for the launch of Arcalyst for the prevention of gout flares.